You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
News and reporting on prostate cancer.
Clinical researchers at AACR discussed a wide range of approaches focusing on several different potential use-cases in the detection or assessment of early cancers.
The projects, set to begin this year, concern prostate cancer, infectious diseases, rheumatoid arthritis, inflammatory bowel disease, heart disease, and sleep disorders.
The company is seeking NY State approval for its lab, which would allow it to offer both tests as LDTs, hopefully by the end of this year or early next.
The firm's EpiSwitch test for blood-based diagnosis of prostate cancer will be evaluated as part of the ongoing PROSTAGRAM trial.
Company officials said they expect the firm's growth momentum to continue in 2019, with increased penetration both in the US and in European markets.
Decipher — formerly GenomeDx Biosciences — will help Dendreon identify patients who are likely to respond to its prostate cancer therapy Provenge.
As part of the agreement, LifeLabs will serve as an exclusive distributor for MDxHealth's non-invasive liquid biopsy prostate cancer assay In Canada.
The federal government said GenomeDx billed Medicare for its Decipher Biopsy prostate cancer genome classifier on behalf of patients who didn't need the test.
Invitae and Tulane University researchers found 37 percent of patients with positive germline results were not covered by testing guidelines in place at the time.
Researchers used exome capture RNA sequencing to come up with a collection of circRNAs in dozens of cancer types, including proposed prostate cancer markers.
The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.
New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.
In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.
Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.